Compare IMCR & DEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IMCR | DEI |
|---|---|---|
| Founded | 2008 | 1971 |
| Country | United Kingdom | United States |
| Employees | 493 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 2021 | 2006 |
| Metric | IMCR | DEI |
|---|---|---|
| Price | $36.13 | $11.20 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 8 |
| Target Price | ★ $67.00 | $15.29 |
| AVG Volume (30 Days) | 259.5K | ★ 1.8M |
| Earning Date | 11-06-2025 | 02-03-2026 |
| Dividend Yield | N/A | ★ 6.79% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.12 |
| Revenue | $379,590,000.00 | ★ $1,000,336,000.00 |
| Revenue This Year | $32.28 | $2.82 |
| Revenue Next Year | $10.66 | $1.67 |
| P/E Ratio | ★ N/A | $89.93 |
| Revenue Growth | ★ 28.11 | 3.61 |
| 52 Week Low | $23.15 | $10.92 |
| 52 Week High | $40.72 | $19.13 |
| Indicator | IMCR | DEI |
|---|---|---|
| Relative Strength Index (RSI) | 48.05 | 32.85 |
| Support Level | $35.41 | $10.92 |
| Resistance Level | $37.25 | $11.22 |
| Average True Range (ATR) | 1.58 | 0.26 |
| MACD | -0.18 | -0.01 |
| Stochastic Oscillator | 20.63 | 18.15 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Douglas Emmett Inc is an integrated, self-administered, and self-managed REIT. It is an owner and operator of office and multifamily properties located in coastal submarkets in Los Angeles and Honolulu. The group focuses on owning, acquiring, developing, and managing a substantial market share of office properties and multifamily communities in neighborhoods with supply constraints, high-end executive housing, and key lifestyle amenities. Its properties are located in the Beverly Hills, Brentwood, Burbank, Century City, Olympic Corridor, Santa Monica, Sherman Oaks/Encino, Warner Center/Woodland Hills and Westwood submarkets of Los Angeles County, California, and in Honolulu, Hawaii. It has two business segments, the office segment and the multifamily segment.